Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated intermediate- or poor-risk advanced/metastatic renal cell carcinoma
NL-OMON58767Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cabozantinib, nivolumab and ipilimumab, sponsored by Exelixis, Inc. Started Jan 2020; status: completed.
02
Drugs
Beyond the preview
Go deeper on NL-OMON58767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58767.